Darbepoetin alfa, a long-acting erythropoietin analog, offers novel and delayed cardioprotection for the ischemic heart.

@article{Gao2007DarbepoetinAA,
  title={Darbepoetin alfa, a long-acting erythropoietin analog, offers novel and delayed cardioprotection for the ischemic heart.},
  author={E. Mei Gao and Matthieu Boucher and J. Kurt Chuprun and Rui-Hai Zhou and Andrea D. Eckhart and Walter J Koch},
  journal={American journal of physiology. Heart and circulatory physiology},
  year={2007},
  volume={293 1},
  pages={H60-8}
}
Recent studies from our lab and others have shown that the hematopoietic cytokine erythropoietin (EPO) can protect the heart from ischemic damage in a red blood cell-independent manner. Here we examined any protective effects of the long-acting EPO analog darbepoetin alfa (DA) in a rat model of ischemia-reperfusion (I/R) injury. Rats were subjected to 30-min ischemia followed by 72-h reperfusion. In a dose-response study, DA (2, 7, 11, and 30 mug/kg) or vehicle was administered as a single… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 47 extracted citations

Acute erythropoietin cardioprotection is mediated by endothelial response

Basic Research in Cardiology • 2011
View 1 Excerpt
Highly Influenced

Similar Papers

Loading similar papers…